Sacituzumab tirumotecan

Sacituzumab tirumotecan (MK-2870, sac-TMT, SKB264) is a TROP2-directed antibody-drug conjugate co-developed by Kelun-Biotech, the Chinese originator, and Merck, which licensed global ex-China rights in May 2022 [9]. This node anchors on NCT06788912, a Phase 2 neoadjuvant substudy (neoadjuvant meaning treatment given before surgery to shrink the tumor) pairing sac-TMT with pembrolizumab (Merck's PD-1 blocker, brand name Keytruda) in resectable non-small cell lung cancer inside Merck's KEYMAKER-U01 umbrella [1]. That specific trial is small and non-randomized, but it sits inside a program that has already produced positive randomized Phase 3 data in PD-L1-positive advanced NSCLC (OptiTROP-Lung05, published Lancet 2026) [2] and in triple-negative breast cancer (OptiTROP-Breast01), plus a China NMPA conditional approval. At least three active Phase 3 trials are running under Merck sponsorship across TNBC, cervical cancer, and adjuvant NSCLC [3][4][5], with additional Phase 3 programs reportedly in HR+/HER2- breast, endometrial, and gastric that are not yet independently verified here. Merck reported roughly $65B in 2025 revenue with about 45% from Keytruda, and sac-TMT is one of the largest post-Keytruda oncology bets in the pipeline [6]. For readers tracking the TROP2 ADC space, this compound is the emerging competitor to Gilead's sacituzumab govitecan (Trodelvy) and AstraZeneca/Daiichi Sankyo's datopotamab deruxtecan (Dato-DXd).

Sacituzumab tirumotecan is a novel compound with no FDA approval in the US as of 2026. In China, Kelun-Biotech received NMPA conditional approval for pretreated metastatic TNBC in 2024 under the SKB264 name. In the US and rest of world, Merck runs the program, and the developmental stage varies by indication: Phase 1 combination work, Phase 2 signal-finding, and at least three confirmed Phase 3 pivotal trials. The specific trial anchoring this record (NCT06788912) is Phase 2, active but not recruiting, with n=60 [1]. That is not the pivotal work. The pivotal work sits in MK-2870-012 (TNBC post-neoadjuvant residual disease, n=1530) [3], MK-2870-019 (resectable NSCLC without pCR after neoadjuvant chemo-IO, n=780) [4], and MK-2870-036 (cervical cancer first-line maintenance with pembro, n=1023) [5]. No US FDA breakthrough, fast track, or accelerated approval designations have been publicly disclosed for sac-TMT specifically, though Merck has not detailed every regulatory interaction. Readouts to watch over the next 24 to 36 months: mature OS from OptiTROP-Lung05 [2], invasive disease-free survival (iDFS, meaning time without cancer returning or dying from any cause) from MK-2870-012 and MK-2870-019, and a Phase 2 urothelial signal already published in Ann Oncol 2026 [7] (PMID unverified, requires lookup before publishing).

TROP2 (encoded by TACSTD2) is a protein that sits on the outer surface of many epithelial cells. It behaves loosely like a growth-signaling receptor: cells that overexpress it tend to proliferate more and metastasize more. Healthy skin, kidney, and lung epithelium carry some TROP2 too, but many carcinomas (breast, lung, cervical, urothelial) crank the expression much higher, which gives an antibody a way to selectively home in on tumor tissue. Sac-TMT is an antibody-drug conjugate: an IgG1 antibody that latches onto TROP2, a hydrolytically cleavable linker, and a topoisomerase I inhibitor payload in the camptothecin class (the same family as Trodelvy's SN-38 payload). Once the antibody binds TROP2 on a tumor cell, the whole complex is dragged inside the cell, the linker is cleaved, and the payload is released. Topoisomerase I inhibitors trap the enzyme mid-cut on DNA during replication, converting single-strand nicks into lethal double-strand breaks. The class is validated: Gilead's sacituzumab govitecan (Trodelvy) is FDA-approved in metastatic TNBC and pretreated urothelial carcinoma. Sac-TMT's drug-to-antibody ratio (~7.4) is approximately comparable to Trodelvy's (~7.6), not higher. The differentiation story rests on linker chemistry and payload potency rather than DAR. Sac-TMT uses a hydrolytically cleavable sulfonyl pyrimidine linker designed for greater stability in systemic circulation compared to Trodelvy's CL2A linker, with the intent of reducing off-target payload release and improving the tolerability window while preserving intratumoral drug release and bystander activity (payload diffusing from initially hit cells into neighboring TROP2-low cells). Whether that translates to a real efficacy or safety delta versus Trodelvy or Dato-DXd is the open question [8]. This characterization of linker stability is directionally reported by Kelun-Biotech and MSD publications; head-to-head PK comparisons are not yet in the peer-reviewed literature.

NCT06788912 (MK-3475-01E, KEYMAKER-U01 substudy 01E) is a Phase 2 open-label substudy inside Merck's pembrolizumab-plus-investigational-agent umbrella in resectable stage II-III NSCLC. Sac-TMT plus pembrolizumab is one of 13 investigational arms. Primary endpoint is pathological complete response (pCR) after neoadjuvant treatment [1]. Enrollment target is ~60, currently active but not recruiting. There is no randomized comparator, no chemo control, no head-to-head against the current standard of neoadjuvant chemo-IO. Design assessment: this is a signal-finder, not a pivotal. pCR in a 60-patient single-arm cohort cannot establish clinical benefit; it exists to pick which combinations are worth graduating to Phase 3. The Phase 3 that flows out of this signal is MK-2870-019 (n=780), which enrolls patients who did NOT achieve pCR after standard neoadjuvant chemo-IO and randomizes them to adjuvant sac-TMT plus pembrolizumab versus pembrolizumab alone, primary endpoint DFS by BICR (blinded independent central review, meaning independent radiologists who assess scan results without knowing which treatment arm a patient is on) [4]. That is a well-designed trial: the population has clear unmet need (post-neoadjuvant residual disease predicts recurrence), the comparator is the actual standard of care, and DFS is a regulatory-acceptable endpoint. The other pivotal Phase 3 trials (MK-2870-012 in TNBC, MK-2870-036 in cervical) follow the same template: pembrolizumab backbone, sac-TMT as the add-on, well-characterized high-risk populations [3][5]. None of these confirmed Phase 3 trials appear to be TROP2-expression-selected; enrollment is based on tumor type and clinical/histologic criteria rather than a TROP2 IHC threshold, which is a design choice worth noting versus Dato-DXd's biomarker-strategy evolution.

Our model estimates a 7% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 13%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by its light or open-label blinding, more secondary endpoints than usual, and the sponsor's strong record of getting drugs approved; it is held back by weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk for the anchor trial: pCR is a surrogate endpoint that correlates well with long-term outcomes in TNBC but inconsistently in NSCLC. Even a meaningful pCR uplift may not translate to Phase 3 DFS or OS gains, and neoadjuvant chemo-IO has already raised the pCR bar substantially. Safety risk: TROP2 ADCs carry mechanism-based toxicities including neutropenia, diarrhea, stomatitis, and interstitial lung disease at low but non-zero rates. In the neoadjuvant window, any toxicity that delays surgery is a hard clinical fail, and adding an ADC on top of pembrolizumab increases that risk. Sac-TMT's Chinese Phase 3 safety profile has been acceptable but not clean, with grade 3+ neutropenia and stomatitis flagged in OptiTROP-Lung05 [2]. Competitive risk: datopotamab deruxtecan is ahead in most Western TROP2 Phase 3 programs, and Trodelvy is entrenched in TNBC with several years of prescriber comfort and a 2024 run rate of approximately $1.3B [10]. A Bayesian indirect comparison published in Value in Health 2026 has already started quantifying sac-TMT versus sacituzumab govitecan in TNBC, and cost-effectiveness will matter for payer coverage [8] (PMID unverified, requires lookup before publishing). Execution risk: multiple simultaneous Phase 3 trials require coordinated readouts and label strategy, and Merck has to sequence indications carefully to avoid cannibalizing Keytruda combinations. Regulatory risk: the FDA has tightened its stance on accelerated approvals for ADCs, particularly around confirmatory trial timing and comparator adequacy. Deal-economics risk for Kelun: under the May 2022 MSD license, Kelun is eligible for up to approximately $82M in developmental milestones, $334M in regulatory milestones, and $485M in sales-based milestones, plus tiered royalties ranging from mid-single-digit to low-double-digit on ex-China net sales [9]. That royalty range is a critical variable for anyone modeling Kelun cash flows against Western commercial success.

Worth watching, and closer to signal than noise. The specific trial anchored here (KEYMAKER-U01 substudy) is a small pathological-response signal-finder and not where the value sits. The datapoints that matter: OptiTROP-Lung05 already delivered a PFS HR of 0.35 (95% CI 0.26 to 0.47, p<0.0001) versus pembrolizumab alone in first-line PD-L1-positive advanced NSCLC (n=413), with median PFS not reached versus 5.7 months and 12-month PFS 62.4% versus 29.0% [2]. That is a large effect size and the first Phase 3 win for an ADC plus checkpoint inhibitor combination in first-line NSCLC. The next major reads are iDFS from MK-2870-012 (TNBC post-residual disease) [3] and MK-2870-019 (adjuvant NSCLC post-residual) [4], both expected 2027 to 2028; mature OS from OptiTROP-Lung05 [2]; and the Phase 3 cervical cancer readout from MK-2870-036 [5]. Strategic urgency for Merck is high: Keytruda's primary US compound patent expires December 2028, with biosimilar competition opening thereafter, so replacement oncology revenue has to be visible before the LOE cliff [11]. Any positive Phase 3 in a Western population would trigger US FDA filing and reprice Merck's post-Keytruda narrative. For market sizing, Trodelvy's approximately $1.3B in 2024 sales [10] is a useful floor for what sac-TMT could displace in TNBC and pretreated urothelial alone; adjuvant NSCLC and first-line NSCLC are orders of magnitude larger opportunities. Kelun-Biotech retains China economics and receives tiered royalties on ex-China sales [9], so it is the smaller but more leveraged play; Merck's roughly $65B revenue base means sac-TMT would need multi-billion-dollar peak sales to move the needle at the corporate level [6]. Check back at each ASCO and ESMO cycle, and at Merck's Q4 2027 update when the first Western Phase 3 iDFS data should be maturing. The compound is the leading Chinese-originated ADC in Western Phase 3 development and will be a test case for how quickly Chinese-originated biologics can reach FDA approval through a large-pharma partnership.